Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Non-cleavable Linker, Cleavable Linker), by Condition (Breast Cancer, Myeloma, Lymphoma) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global antibody drug conjugates contract manufacturing market was valued at USD 7.2 billion in 2020. It is projected to grow at 12.3% compound annual growth rate (CAGR), between 2021 and 2028. Due to the rising incidence of cancer and the increased demand for biologic therapy as well as outsourcing operations and services to contract manufacturers, the market is expected to experience significant growth during the forecast period.
Many chemotherapy drugs have toxicities that can cause severe side effects. This can limit the effectiveness and dosage of the medication and place a substantial burden on patients. These side effects can be reduced by using an antibody drug conjugate. Antibody Drug Conjugates, also known as Antibody Drug Conjugates (ADC), allow the delivery of a particular medication dose to a site of interest. These are used most frequently in oncology, where a large dosage of medication is needed at the tumor site and not in adjacent tissue.
COVID-19 had a significant impact on healthcare, causing disruptions in the entire supply chain from raw materials to production and delivery. Major market players are involved in research and development, strategic alliances, collaborations and product launches to satisfy consumer needs for medicines, vaccinations, diagnostics and medical equipment.
CMOs can provide technical expertise in linker creation and conjugation, as well as solid platforms. An integrated CMO reduces the time it takes for an ADC to go to market. They can manage all stages of conjugation, scale up, commercial production, fill-finish, as well as scheduling and testing. ImmunoGen made the switch to outsource manufacturing of its ADCs in October 2018. This was due to the increased expertise provided by a CMO. The savings totalled $20 million.
The active pharmaceutical component industry (API), which was dominated historically by small-molecule drugs, is shifting rapidly towards biopharmaceuticals. The volume of production being outsourced to contract manufacturers is also increasing. Because of the complexity of manufacturing processes and concerns over intellectual property, biologics are made in-house. This has an impact on contract manufacturing businesses.
Condition Insights
Myeloma dominated the market, accounting for 49.4% of the total revenue in 2020. Market growth is affected by antibody drug conjugates. This treatment, which delivers a powerful cytotoxic chemical directly into the myeloma cells, is a new type of treatment for myeloma sufferers.
Target is defined by the specificity of the monoclonal antibodies that are linked to the cytotoxic chemicals. This mechanism of action decreases cell damage by non-target cells and opens up therapeutic possibilities. ADCs are a viable option for myeloma treatment as they are 'off-the-shelf' therapies. It can be used in nearly all myeloma treatment centers and for a wide range of patients.
Linker Insights
In 2020, the market for ADC contract manufacture was dominated by the cleavable linking segment. It accounted for 56.5% of the total revenue. This segment will likely continue to be dominant in the future. The advantages that cleavable links offer in certain situations to deliver the medication to the targeted cell is a major factor in the segment's growth. An ADC's success is determined by the characteristics of the linker between antibody and payload. Its effectiveness is attributed to its ability to distinguish between target-cell and circulatory conditions using cleavable links.
The segment with non-cleavable links is expected to see the fastest CAGR at 12.5% during the forecast period. ADCs that use non-cleavable linksers are more dependent on the biology of target cells. Plasma stability is higher for non-cleavable links than for cleavable, which can be beneficial in enhancing the therapeutic index.
Regional Insights
Asia Pacific was the dominant market for ADC contract manufacturing and held the largest revenue share at 46.4% in 2020. Over the forecast period, the region will experience the fastest growth rate at 14.6%. Asia Pacific is responsible for 48.0% worldwide new cases of cancer, with China accounting almost half of these cases. Similar to the rest of the world, 55.0% are killed by cancer in Asia. In Asia, the incidence and death of cancer are expected to rise over the next 20 years.
Asia Pacific is the fastest growing pharmaceutical market in the world, offering huge potential for drug research and commercialization. This is why pharmaceutical regulations in the region are drawing a lot attention from pharmaceutical companies around the world. The growth of the regional market is due to the increased outsourcing of manufacturing operations to contract manufacturing companies.
Market Share Insights and Key Companies
To increase their market share, key players are pursuing strategic alliances that include mergers and acquisitions as well as collaborations and partnerships with market players. Cambrex Corporation announced in August 2019 that it had signed a formal agreement for Permira funds to purchase Cambrex Corporation. The transaction was valued at $2.4 million. Cambrex Corporation is unique in that it provides clinical trial materials for COVID-19 purposes to innovators. It also handles significant pressure when delivering goods during shortages of raw material or supply chain. The following are some of the most prominent players in antibody drug conjugates contract manufacture market:
-
Samsung Biologics
-
Lonza
-
Catalent
-
Siegfried
-
Piramal Pharma Solutions
-
Boehringer Ingelheim
Up Market Research published a new report titled “Antibody Drug Conjugates Contract Manufacturing Market research report which is segmented by Linker (Non-cleavable Linker, Cleavable Linker), by Condition (Breast Cancer, Myeloma, Lymphoma), By Players/Companies Piramal Pharma Solutions, Samsung Biologics, Boehringer Ingelheim, Lonza, Siegfried, Catalent”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Antibody Drug Conjugates Contract Manufacturing Market Research Report |
| By Linker | Non-cleavable Linker, Cleavable Linker |
| By Condition | Breast Cancer, Myeloma, Lymphoma |
| By Companies | Piramal Pharma Solutions, Samsung Biologics, Boehringer Ingelheim, Lonza, Siegfried, Catalent |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 248 |
| Number of Tables & Figures | 174 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Antibody Drug Conjugates Contract Manufacturing Market Report Segments:
The market is segmented by Linker (Non-cleavable Linker, Cleavable Linker), by Condition (Breast Cancer, Myeloma, Lymphoma).
Antibody Drug Conjugates Contract Manufacturing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Antibody Drug Conjugates Contract Manufacturing Market
Overview of the regional outlook of the Antibody Drug Conjugates Contract Manufacturing Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Antibody Drug Conjugates Contract Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Antibody Drug Conjugates Contract Manufacturing Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Non-cleavable Linker
2. Cleavable Linker
7. By Condition:1. Breast Cancer
2. Myeloma
3. Lymphoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antibody Drug Conjugates Contract Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Antibody Drug Conjugates Contract Manufacturing Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antibody Drug Conjugates Contract Manufacturing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antibody Drug Conjugates Contract Manufacturing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antibody Drug Conjugates Contract Manufacturing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antibody Drug Conjugates Contract Manufacturing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antibody Drug Conjugates Contract Manufacturing Market Size & Forecast, 2018-2028
4.5.1 Antibody Drug Conjugates Contract Manufacturing Market Size and Y-o-Y Growth
4.5.2 Antibody Drug Conjugates Contract Manufacturing Market Absolute $ Opportunity
Chapter 5 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Linker
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Linker
5.1.2 Basis Point Share (BPS) Analysis by Linker
5.1.3 Absolute $ Opportunity Assessment by Linker
5.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
5.2.1 Non-cleavable Linker
5.2.2 Cleavable Linker
5.3 Market Attractiveness Analysis by Linker
Chapter 6 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Condition
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Condition
6.1.2 Basis Point Share (BPS) Analysis by Condition
6.1.3 Absolute $ Opportunity Assessment by Condition
6.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
6.2.1 Breast Cancer
6.2.2 Myeloma
6.2.3 Lymphoma
6.3 Market Attractiveness Analysis by Condition
Chapter 7 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
9.1 Introduction
9.2 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
9.6.1 Non-cleavable Linker
9.6.2 Cleavable Linker
9.7 Basis Point Share (BPS) Analysis by Linker
9.8 Absolute $ Opportunity Assessment by Linker
9.9 Market Attractiveness Analysis by Linker
9.10 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
9.10.1 Breast Cancer
9.10.2 Myeloma
9.10.3 Lymphoma
9.11 Basis Point Share (BPS) Analysis by Condition
9.12 Absolute $ Opportunity Assessment by Condition
9.13 Market Attractiveness Analysis by Condition
Chapter 10 Europe Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
10.1 Introduction
10.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
10.6.1 Non-cleavable Linker
10.6.2 Cleavable Linker
10.7 Basis Point Share (BPS) Analysis by Linker
10.8 Absolute $ Opportunity Assessment by Linker
10.9 Market Attractiveness Analysis by Linker
10.10 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
10.10.1 Breast Cancer
10.10.2 Myeloma
10.10.3 Lymphoma
10.11 Basis Point Share (BPS) Analysis by Condition
10.12 Absolute $ Opportunity Assessment by Condition
10.13 Market Attractiveness Analysis by Condition
Chapter 11 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
11.6.1 Non-cleavable Linker
11.6.2 Cleavable Linker
11.7 Basis Point Share (BPS) Analysis by Linker
11.8 Absolute $ Opportunity Assessment by Linker
11.9 Market Attractiveness Analysis by Linker
11.10 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
11.10.1 Breast Cancer
11.10.2 Myeloma
11.10.3 Lymphoma
11.11 Basis Point Share (BPS) Analysis by Condition
11.12 Absolute $ Opportunity Assessment by Condition
11.13 Market Attractiveness Analysis by Condition
Chapter 12 Latin America Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
12.1 Introduction
12.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
12.6.1 Non-cleavable Linker
12.6.2 Cleavable Linker
12.7 Basis Point Share (BPS) Analysis by Linker
12.8 Absolute $ Opportunity Assessment by Linker
12.9 Market Attractiveness Analysis by Linker
12.10 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
12.10.1 Breast Cancer
12.10.2 Myeloma
12.10.3 Lymphoma
12.11 Basis Point Share (BPS) Analysis by Condition
12.12 Absolute $ Opportunity Assessment by Condition
12.13 Market Attractiveness Analysis by Condition
Chapter 13 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
13.6.1 Non-cleavable Linker
13.6.2 Cleavable Linker
13.7 Basis Point Share (BPS) Analysis by Linker
13.8 Absolute $ Opportunity Assessment by Linker
13.9 Market Attractiveness Analysis by Linker
13.10 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
13.10.1 Breast Cancer
13.10.2 Myeloma
13.10.3 Lymphoma
13.11 Basis Point Share (BPS) Analysis by Condition
13.12 Absolute $ Opportunity Assessment by Condition
13.13 Market Attractiveness Analysis by Condition
Chapter 14 Competition Landscape
14.1 Antibody Drug Conjugates Contract Manufacturing Market: Competitive Dashboard
14.2 Global Antibody Drug Conjugates Contract Manufacturing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Piramal Pharma Solutions
14.3.2 Samsung Biologics
14.3.3 Boehringer Ingelheim
14.3.4 Lonza
14.3.5 Siegfried
14.3.6 Catalent
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antibody Drug Conjugates Contract Manufacturing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antibody Drug Conjugates Contract Manufacturing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antibody Drug Conjugates Contract Manufacturing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antibody Drug Conjugates Contract Manufacturing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antibody Drug Conjugates Contract Manufacturing Market Size & Forecast, 2018-2028
4.5.1 Antibody Drug Conjugates Contract Manufacturing Market Size and Y-o-Y Growth
4.5.2 Antibody Drug Conjugates Contract Manufacturing Market Absolute $ Opportunity
Chapter 5 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Linker
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Linker
5.1.2 Basis Point Share (BPS) Analysis by Linker
5.1.3 Absolute $ Opportunity Assessment by Linker
5.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
5.2.1 Non-cleavable Linker
5.2.2 Cleavable Linker
5.3 Market Attractiveness Analysis by Linker
Chapter 6 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Condition
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Condition
6.1.2 Basis Point Share (BPS) Analysis by Condition
6.1.3 Absolute $ Opportunity Assessment by Condition
6.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
6.2.1 Breast Cancer
6.2.2 Myeloma
6.2.3 Lymphoma
6.3 Market Attractiveness Analysis by Condition
Chapter 7 Global Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
9.1 Introduction
9.2 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
9.6.1 Non-cleavable Linker
9.6.2 Cleavable Linker
9.7 Basis Point Share (BPS) Analysis by Linker
9.8 Absolute $ Opportunity Assessment by Linker
9.9 Market Attractiveness Analysis by Linker
9.10 North America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
9.10.1 Breast Cancer
9.10.2 Myeloma
9.10.3 Lymphoma
9.11 Basis Point Share (BPS) Analysis by Condition
9.12 Absolute $ Opportunity Assessment by Condition
9.13 Market Attractiveness Analysis by Condition
Chapter 10 Europe Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
10.1 Introduction
10.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
10.6.1 Non-cleavable Linker
10.6.2 Cleavable Linker
10.7 Basis Point Share (BPS) Analysis by Linker
10.8 Absolute $ Opportunity Assessment by Linker
10.9 Market Attractiveness Analysis by Linker
10.10 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
10.10.1 Breast Cancer
10.10.2 Myeloma
10.10.3 Lymphoma
10.11 Basis Point Share (BPS) Analysis by Condition
10.12 Absolute $ Opportunity Assessment by Condition
10.13 Market Attractiveness Analysis by Condition
Chapter 11 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
11.6.1 Non-cleavable Linker
11.6.2 Cleavable Linker
11.7 Basis Point Share (BPS) Analysis by Linker
11.8 Absolute $ Opportunity Assessment by Linker
11.9 Market Attractiveness Analysis by Linker
11.10 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
11.10.1 Breast Cancer
11.10.2 Myeloma
11.10.3 Lymphoma
11.11 Basis Point Share (BPS) Analysis by Condition
11.12 Absolute $ Opportunity Assessment by Condition
11.13 Market Attractiveness Analysis by Condition
Chapter 12 Latin America Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
12.1 Introduction
12.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
12.6.1 Non-cleavable Linker
12.6.2 Cleavable Linker
12.7 Basis Point Share (BPS) Analysis by Linker
12.8 Absolute $ Opportunity Assessment by Linker
12.9 Market Attractiveness Analysis by Linker
12.10 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
12.10.1 Breast Cancer
12.10.2 Myeloma
12.10.3 Lymphoma
12.11 Basis Point Share (BPS) Analysis by Condition
12.12 Absolute $ Opportunity Assessment by Condition
12.13 Market Attractiveness Analysis by Condition
Chapter 13 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Linker
13.6.1 Non-cleavable Linker
13.6.2 Cleavable Linker
13.7 Basis Point Share (BPS) Analysis by Linker
13.8 Absolute $ Opportunity Assessment by Linker
13.9 Market Attractiveness Analysis by Linker
13.10 Middle East & Africa (MEA) Antibody Drug Conjugates Contract Manufacturing Market Size Forecast by Condition
13.10.1 Breast Cancer
13.10.2 Myeloma
13.10.3 Lymphoma
13.11 Basis Point Share (BPS) Analysis by Condition
13.12 Absolute $ Opportunity Assessment by Condition
13.13 Market Attractiveness Analysis by Condition
Chapter 14 Competition Landscape
14.1 Antibody Drug Conjugates Contract Manufacturing Market: Competitive Dashboard
14.2 Global Antibody Drug Conjugates Contract Manufacturing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Piramal Pharma Solutions
14.3.2 Samsung Biologics
14.3.3 Boehringer Ingelheim
14.3.4 Lonza
14.3.5 Siegfried
14.3.6 Catalent
Segments Covered in the Report
The global Antibody Drug Conjugates Contract Manufacturing market has been segmented based on
By Linker
The global Antibody Drug Conjugates Contract Manufacturing market has been segmented based on
By Linker
- Non-cleavable Linker
- Cleavable Linker
- Breast Cancer
- Myeloma
- Lymphoma
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Piramal Pharma Solutions
- Samsung Biologics
- Boehringer Ingelheim
- Lonza
- Siegfried
- Catalent
Our Clients
Related Reports
Some other reports from this category!
